ClinicalTrials.gg
CompletedNCT03571607Updated Feb 18, 2020Results posted

A Safety And Immunogenicity Study Of A 13-valent Pneumococcal Conjugate Vaccine In Japanese Subjects Aged 6 To 64 Years.

A Phase 3 interventional study of 13-valent pneumococcal conjugate vaccine in Pneumococcal Infections, sponsored by Pfizer. Completed at 8 sites in Japan. Open to participants aged 6 Years to 64 Years. Per ClinicalTrials.gov, last updated 2020-02-18.

Sponsored by Pfizer · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
206
Allocation
Not applicable
Ages
6 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 44 studies testing 13-valent pneumococcal vaccine in Pneumococcal Infections — none open to participants now, 1 under way, none of them phase 3. 13-valent pneumococcal vaccine · Pneumococcal Infections.

Enrollment
32nd of 44
206 · median 328
Started
2018
with 5 others
Phase 3
19 of 44
none open now
Registered
34th of 44
by date
Lead sponsor
16 of 44
Pfizer

Among the 44 studies testing 13-valent pneumococcal vaccine in Pneumococcal Infections, this one is the 32nd largest by enrollment, is one of 6 that started in 2018, is one of 19 in phase 3, and was the 34th registered.

Pneumococcal Infections

298 studies on the registry are indexed under Pneumococcal Infections; 25 are open to participants now.

Browse Pneumococcal Infections studies →

Open to participants now

None of the 44 studies testing 13-valent pneumococcal vaccine in Pneumococcal Infections is open now. The open studies under Pneumococcal Infections, anywhere →

About 13-valent pneumococcal vaccine

13-valent pneumococcal vaccine: first FDA approval 2010 (Prevnar 13). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 20 Pneumococcal Infections studies recruiting now, 4 (20%) set no upper age limit and 14 (70%) stop at 75 or younger; 14 take children under 18; 16 take healthy volunteers.

This study: 6 Years to 64 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 44 studies testing 13-valent pneumococcal vaccine in Pneumococcal Infections as a file.
02

Study summary

This study is to evaluate the safety, tolerability and immunogenicity of a single dose of 13-valent pneumococcal conjugate vaccine in Japanese subjects aged 6 to 64 years who are considered to be at increased risk of pneumococcal disease and who are naive to pneumococcal vaccines.

03

Conditions studied

  • Pneumococcal Infections
04

Who can participate

Ages eligible
6 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Japanese males and females aged 6 to \<65 years at enrollment.
  • Subjects with an increased risk of pneumococcal disease determined by documented medical history, physical examination, and clinical judgment of the investigator.

Exclusion criteria

Exclusion Criteria:

  • Previous vaccination with any licensed or pneumococcal vaccine, or planned receipt during study participation.
  • End-stage disease including but not limited to , severe (COPD) requiring supplemental oxygen, or end-stage renal disease with or without dialysis.
  • (GVHD), history of solid organ transplant within 6 months before investigational product administration or history of , or potential for solid organ transplant or HSCT during study participation.
  • Receipt of cytotoxic chemotherapy or blood products within 3 months before investigational product administration or anti-B-cell antibodies within 6 months before investigational product administration through completion of study participation.
  • Any to vaccination or vaccine components, including previous anaphylactic reaction to any vaccine or vaccine-related components.
  • Documented S pneumoniae infection within the past 5 years before investigational product administration.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
206 participants (actual)

Study arms

  • Experimental
    13-valent pneumococcal conjugate vaccine

    Biological: 13-valent pneumococcal conjugate vaccine

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Reporting Pre-Specified Local Reactions Within 7 Days After Vaccination in Participants Aged Between 6 to <18 Years

    Local reactions were recorded using an electronic daily diary. Local reactions included redness, swelling and pain at injection site. Redness and swelling were graded as mild (0.5 to 2.0 centimeter \[cm\]), moderate (greater than \[\>\] 2.0 to 7.0 cm) and severe (\>7.0 cm) for participants aged 6 to \<12 years, and as mild (2.5 to 5.0 cm), moderate (\>5.0 to 10.0 cm) and, severe (\>10.0 cm) for participants aged 12 to \<18 years. Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), and severe (prevented daily activity).

    Time frame: Day 1 up to Day 7

  2. Percentage of Participants Reporting Pre-Specified Local Reactions Within 14 Days After Vaccination in Participants Aged Between 18 to <65 Years

    Local reactions were recorded using an electronic daily diary. Local reactions included redness, swelling and pain at injection site. Redness and swelling were graded as mild (2.5 to 5.0 cm), moderate (\>5.0 to 10.0 cm) and, severe (\>10.0 cm). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), and severe (prevented daily activity).

    Time frame: Day 1 up to Day 14

  3. Percentage of Participants Reporting Systemic Events and Use of Antipyretic or Pain Medication Within 7 Days After Vaccination in Participants Aged Between 6 to <18 Years

    Systemic events included fever, vomiting, diarrhea, headache, fatigue, muscle and joint pain, and were recorded by using an e-diary. Use of antipyretic or pain medication was also collected by using an e-diary. Fever was graded as 37.5 to 38.4 degree Celsius (C), 38.5 to 38.9 degree C, 39.0 to 40.0 degree C and \>40.0 degree C. Vomiting was graded as mild (1-2 times in 24 hours), moderate (\>2 times in 24 hours) and severe (required intravenous hydration). Diarrhea was graded as mild (2-3 loose stools in 24 hours), moderate (4-5 loose stools in 24 hours) and severe (greater than or equals to \[\>=\] 6 loose stools in 24 hours). Headache, fatigue, muscle pain and joint pain were graded as mild (no interference with activity), moderate (some interference with activity) and severe (significant, prevented daily activity).

    Time frame: Day 1 up to Day 7

  4. Percentage of Participants Reporting Systemic Events and Use of Antipyretic or Pain Medication Within 14 Days After Vaccination in Participants Aged Between 18 to <65 Years

    Systemic events included fever, vomiting, diarrhea, headache, fatigue, muscle and joint pain, and were recorded by using an e-diary. Use of antipyretic or pain medication was also collected by using an e-diary. Fever was graded as 37.5 to 38.4 degree C, 38.5 to 38.9 degree C, 39.0 to 40.0 degree C and \>40.0 degree C. Vomiting was graded as mild (1-2 times in 24 hours), moderate (\>2 times in 24 hours) and severe (required intravenous hydration). Diarrhea was graded as mild (2-3 loose stools in 24 hours), moderate (4-5 loose stools in 24 hours) and severe (\>=6 loose stools in 24 hours). Headache, fatigue, muscle pain and joint pain were graded as mild (no interference with activity), moderate (some interference with activity) and severe (significant, prevented daily activity).

    Time frame: Day 1 up to Day 14

  5. Percentage of Participants Reporting Adverse Events (AEs) and Serious Adverse Events (SAEs)

    An AE was any untoward medical occurrence in a participant who received study vaccine without regard to possibility of causal relationship. An SAE is any untoward medical occurrence at any dose that results in death; is life-threatening (immediate risk of death); requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions); results in congenital anomaly/birth defect.

    Time frame: signing of informed consent form (Day 1) up to Day 43

Secondary outcomes

  1. Serotype-specific Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) at Pre-vaccination and 1 Month After Vaccination

    Antibody-mediated serum OPA against each of the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) was measured centrally using a quantitative functional microcolony OPA (mcOPA) assay. Results were expressed as OPA titers. OPA titers were logarithmically transformed for analysis; geometric means calculated and expressed as geometric mean titers (GMTs). Two (2)-sided 95% CIs were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed based on the Student t distribution. OPA titer was expressed as reciprocal of highest serum dilution.

    Time frame: Pre-vaccination and 1 month after vaccination

  2. Geometric Mean Fold Rises (GMFRs) in Serotype-specific OPA Titers 1 Month After Vaccination

    OPA GMFRs were calculated along with corresponding 2-sided 95% CIs for pneumococcal serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F. GMFRs were computed as the fold rise in titer value at 1 month after vaccination compared to baseline (pre-vaccination). The CIs for GMFRs were back transformations of a CI based on the Student t distribution for the mean difference of the log-transformed assay results before vaccination and 1 month after vaccination.

    Time frame: Pre-vaccination to 1 month after vaccination

  3. Serotype-specific Immunoglobulin G (IgG) Geometric Mean Concentrations (GMCs) at Pre-vaccination and 1 Month After Vaccination

    Pneumococcal IgG antibody against each of the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) was measured centrally using direct binding Luminex assay. Results were expressed as IgG concentrations. IgG concentrations were logarithmically transformed for analysis; geometric means calculated and expressed as GMCs. Two (2)-sided 95% CIs were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed based on the Student t distribution.

    Time frame: Pre-vaccination and 1 month after vaccination

  4. GMFRs in Serotype-specific IgG From Before Vaccination to 1 Month After Vaccination

    IgG GMFRs were calculated along with corresponding 2-sided 95% CIs for pneumococcal serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F. GMFRs were computed as the fold rise in concentrations at 1 month after vaccination compared to baseline (pre-vaccination). The CIs for GMFRs were back transformations of a CI based on the Student t distribution for the mean difference of the log-transformed assay results before vaccination and 1 month after vaccination.

    Time frame: Pre- vaccination to 1 month after vaccination

07

Results

Posted Dec 10, 2019

Participant flow

Participant flow — Overall Study
Milestone13vPnC: 6 to <18 Years13vPnC: 18 to <65 Years
Started53153
Vaccinated53153
Completed53153
Not completed00

Outcome measures

PrimaryPercentage of Participants Reporting Pre-Specified Local Reactions Within 7 Days After Vaccination in Participants Aged Between 6 to <18 Years

Local reactions were recorded using an electronic daily diary. Local reactions included redness, swelling and pain at injection site. Redness and swelling were graded as mild (0.5 to 2.0 centimeter \[cm\]), moderate (greater than \[\>\] 2.0 to 7.0 cm) and severe (\>7.0 cm) for participants aged 6 to \<12 years, and as mild (2.5 to 5.0 cm), moderate (\>5.0 to 10.0 cm) and, severe (\>10.0 cm) for participants aged 12 to \<18 years. Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), and severe (prevented daily activity).

Time frame:
Day 1 up to Day 7
Reported as:
Number · percentage of participants
Percentage of Participants Reporting Pre-Specified Local Reactions Within 7 Days After Vaccination in Participants Aged Between 6 to <18 Years
percentage of participants13vPnC: 6 to <18 Years
Redness: Any21.3 (10.7 to 35.7)
Redness: Mild10.6 (3.5 to 23.1)
Redness: Moderate10.6 (3.5 to 23.1)
Redness: Severe0.0 (0.0 to 7.5)
Swelling: Any34.0 (20.9 to 49.3)
Swelling: Mild14.9 (6.2 to 28.3)
Swelling: Moderate17.0 (7.6 to 30.8)
Swelling: Severe2.1 (0.1 to 11.3)
Pain at the injection site: Any78.8 (65.3 to 88.9)
Pain at the injection site: Mild57.7 (43.2 to 71.3)
Pain at the injection site: Moderate21.2 (11.1 to 34.7)
Pain at the injection site: Severe0.0 (0.0 to 6.8)
PrimaryPercentage of Participants Reporting Pre-Specified Local Reactions Within 14 Days After Vaccination in Participants Aged Between 18 to <65 Years

Local reactions were recorded using an electronic daily diary. Local reactions included redness, swelling and pain at injection site. Redness and swelling were graded as mild (2.5 to 5.0 cm), moderate (\>5.0 to 10.0 cm) and, severe (\>10.0 cm). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), and severe (prevented daily activity).

Time frame:
Day 1 up to Day 14
Reported as:
Number · percentage of participants
Percentage of Participants Reporting Pre-Specified Local Reactions Within 14 Days After Vaccination in Participants Aged Between 18 to <65 Years
percentage of participants13vPnC: 18 to <65 Years
Redness: Any7.4 (3.6 to 13.2)
Redness: Mild5.2 (2.1 to 10.4)
Redness: Moderate2.2 (0.5 to 6.4)
Redness: Severe0.0 (0.0 to 2.7)
Swelling: Any12.5 (7.5 to 19.3)
Swelling: Mild5.1 (2.1 to 10.3)
Swelling: Moderate7.4 (3.6 to 13.1)
Swelling: Severe0.0 (0.0 to 2.7)
Pain at the injection site: Any66.2 (57.9 to 73.8)
Pain at the injection site: Mild53.8 (45.3 to 62.1)
Pain at the injection site: Moderate11.0 (6.4 to 17.3)
Pain at the injection site: Severe1.4 (0.2 to 4.9)
PrimaryPercentage of Participants Reporting Systemic Events and Use of Antipyretic or Pain Medication Within 7 Days After Vaccination in Participants Aged Between 6 to <18 Years

Systemic events included fever, vomiting, diarrhea, headache, fatigue, muscle and joint pain, and were recorded by using an e-diary. Use of antipyretic or pain medication was also collected by using an e-diary. Fever was graded as 37.5 to 38.4 degree Celsius (C), 38.5 to 38.9 degree C, 39.0 to 40.0 degree C and \>40.0 degree C. Vomiting was graded as mild (1-2 times in 24 hours), moderate (\>2 times in 24 hours) and severe (required intravenous hydration). Diarrhea was graded as mild (2-3 loose stools in 24 hours), moderate (4-5 loose stools in 24 hours) and severe (greater than or equals to \[\>=\] 6 loose stools in 24 hours). Headache, fatigue, muscle pain and joint pain were graded as mild (no interference with activity), moderate (some interference with activity) and severe (significant, prevented daily activity).

Time frame:
Day 1 up to Day 7
Reported as:
Number · percentage of participants
Percentage of Participants Reporting Systemic Events and Use of Antipyretic or Pain Medication Within 7 Days After Vaccination in Participants Aged Between 6 to <18 Years
percentage of participants13vPnC: 6 to <18 Years
Fever: 37.5 degree C to 38.4 degree C12.5 (4.7 to 25.2)
Fever: 38.5 degree C to 38.9 degree C2.1 (0.1 to 11.1)
Fever: 39.0 degree C to 40.0 degree C0.0 (0.0 to 7.4)
Fever: >40.0 degree C0.0 (0.0 to 7.4)
Fatigue: Any37.5 (24.0 to 52.6)
Fatigue: Mild25.0 (13.6 to 39.6)
Fatigue: Moderate10.4 (3.5 to 22.7)
Fatigue: Severe2.1 (0.1 to 11.1)
Headache: Any24.5 (13.3 to 38.9)
Headache: Mild16.3 (7.3 to 29.7)
Headache: Moderate6.1 (1.3 to 16.9)
Headache: Severe2.0 (0.1 to 10.9)
Vomiting: Any0.0 (0.0 to 7.5)
Vomiting: Mild0.0 (0.0 to 7.5)
Vomiting: Moderate0.0 (0.0 to 7.5)
Vomiting: Severe0.0 (0.0 to 7.5)
Diarrhea: Any8.3 (2.3 to 20.0)
Diarrhea: Mild8.3 (2.3 to 20.0)
Diarrhea: Moderate0.0 (0.0 to 7.4)
Diarrhea: Severe0.0 (0.0 to 7.4)
Muscle pain: Any30.6 (18.3 to 45.4)
Muscle pain: Mild26.5 (14.9 to 41.1)
Muscle pain: Moderate4.1 (0.5 to 14.0)
Muscle pain: Severe0.0 (0.0 to 7.3)
Joint pain: Any6.3 (1.3 to 17.2)
Joint pain: Mild4.2 (0.5 to 14.3)
Joint pain: Moderate2.1 (0.1 to 11.1)
Joint pain: Severe0.0 (0.0 to 7.4)
Use of antipyretic or pain medication6.4 (1.3 to 17.5)
PrimaryPercentage of Participants Reporting Systemic Events and Use of Antipyretic or Pain Medication Within 14 Days After Vaccination in Participants Aged Between 18 to <65 Years

Systemic events included fever, vomiting, diarrhea, headache, fatigue, muscle and joint pain, and were recorded by using an e-diary. Use of antipyretic or pain medication was also collected by using an e-diary. Fever was graded as 37.5 to 38.4 degree C, 38.5 to 38.9 degree C, 39.0 to 40.0 degree C and \>40.0 degree C. Vomiting was graded as mild (1-2 times in 24 hours), moderate (\>2 times in 24 hours) and severe (required intravenous hydration). Diarrhea was graded as mild (2-3 loose stools in 24 hours), moderate (4-5 loose stools in 24 hours) and severe (\>=6 loose stools in 24 hours). Headache, fatigue, muscle pain and joint pain were graded as mild (no interference with activity), moderate (some interference with activity) and severe (significant, prevented daily activity).

Time frame:
Day 1 up to Day 14
Reported as:
Number · percentage of participants
Percentage of Participants Reporting Systemic Events and Use of Antipyretic or Pain Medication Within 14 Days After Vaccination in Participants Aged Between 18 to <65 Years
percentage of participants13vPnC: 18 to <65 Years
Fever: 37.5 degree C to 38.4 degree C6.0 (2.6 to 11.4)
Fever: 38.5 degree C to 38.9 degree C0.0 (0.0 to 2.7)
Fever: 39.0 degree C to 40.0 degree C0.0 (0.0 to 2.7)
Fever: >40.0 degree C0.0 (0.0 to 2.7)
Fatigue: Any33.1 (25.4 to 41.5)
Fatigue: Mild25.4 (18.4 to 33.3)
Fatigue: Moderate7.7 (3.9 to 13.4)
Fatigue: Severe0.0 (0.0 to 2.6)
Headache: Any23.4 (16.7 to 31.3)
Headache: Mild19.1 (13.0 to 26.6)
Headache: Moderate4.3 (1.6 to 9.0)
Headache: Severe0.0 (0.0 to 2.6)
Vomiting: Any1.5 (0.2 to 5.2)
Vomiting: Mild1.5 (0.2 to 5.2)
Vomiting: Moderate0.0 (0.0 to 2.7)
Vomiting: Severe0.0 (0.0 to 2.7)
Diarrhea: Any18.4 (12.4 to 25.8)
Diarrhea: Mild15.6 (10.0 to 22.7)
Diarrhea: Moderate2.1 (0.4 to 6.1)
Diarrhea: Severe0.7 (0.0 to 3.9)
Muscle pain: Any27.3 (20.1 to 35.5)
Muscle pain: Mild20.9 (14.4 to 28.6)
Muscle pain: Moderate5.8 (2.5 to 11.0)
Muscle pain: Severe0.7 (0.0 to 3.9)
Joint pain: Any13.8 (8.5 to 20.7)
Joint pain: Mild9.4 (5.1 to 15.6)
Joint pain: Moderate3.6 (1.2 to 8.3)
Joint pain: Severe0.7 (0.0 to 4.0)
Use of antipyretic or pain medication8.2 (4.2 to 14.2)
PrimaryPercentage of Participants Reporting Adverse Events (AEs) and Serious Adverse Events (SAEs)

An AE was any untoward medical occurrence in a participant who received study vaccine without regard to possibility of causal relationship. An SAE is any untoward medical occurrence at any dose that results in death; is life-threatening (immediate risk of death); requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions); results in congenital anomaly/birth defect.

Time frame:
signing of informed consent form (Day 1) up to Day 43
Reported as:
Number · percentage of participants
Percentage of Participants Reporting Adverse Events (AEs) and Serious Adverse Events (SAEs)
percentage of participants13vPnC: All Participants
AEs16
SAEs0
SecondarySerotype-specific Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) at Pre-vaccination and 1 Month After Vaccination

Antibody-mediated serum OPA against each of the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) was measured centrally using a quantitative functional microcolony OPA (mcOPA) assay. Results were expressed as OPA titers. OPA titers were logarithmically transformed for analysis; geometric means calculated and expressed as geometric mean titers (GMTs). Two (2)-sided 95% CIs were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed based on the Student t distribution. OPA titer was expressed as reciprocal of highest serum dilution.

Time frame:
Pre-vaccination and 1 month after vaccination
Reported as:
Geometric mean · titers
Serotype-specific Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) at Pre-vaccination and 1 Month After Vaccination
titers13vPnC: All Participants
Pre-vaccination; Serotype 110 (9.2 to 10.2)
1 month after vaccination; Serotype 1152 (119.2 to 193.8)
Pre-vaccination; Serotype 311 (9.8 to 13.1)
1 month after vaccination; Serotype 363 (52.6 to 75.8)
Pre-vaccination; Serotype 418 (14.5 to 22.1)
1 month after vaccination; Serotype 41257 (896.0 to 1763.8)
Pre-vaccination; Serotype 516 (15.3 to 17.5)
1 month after vaccination; Serotype 5185 (143.9 to 237.5)
Pre-vaccination; Serotype 6A57 (44.1 to 74.9)
1 month after vaccination; Serotype 6A2487 (1811.7 to 3415.0)
Pre-vaccination; Serotype 6B72 (56.3 to 93.0)
1 month after vaccination; Serotype 6B1845 (1405.9 to 2421.9)
Pre-vaccination; Serotype 7F167 (137.0 to 203.3)
1 month after vaccination; Serotype 7F2107 (1752.6 to 2532.5)
Pre-vaccination; Serotype 9V204 (166.6 to 249.7)
1 month after vaccination; Serotype 9V1425 (1134.4 to 1789.8)
Pre-vaccination; Serotype 14129 (97.9 to 171.1)
1 month after vaccination; Serotype 141919 (1518.8 to 2424.0)
Pre-vaccination; Serotype 18C61 (46.3 to 81.0)
1 month after vaccination; Serotype 18C1829 (1390.8 to 2405.1)
Pre-vaccination; Serotype 19A38 (29.9 to 47.8)
1 month after vaccination; Serotype 19A955 (745.6 to 1223.2)
Pre-vaccination; Serotype 19F42 (34.8 to 50.4)
1 month after vaccination; Serotype 19F1126 (849.5 to 1493.4)
Pre-vaccination; Serotype 23F14 (11.1 to 17.2)
1 month after vaccination; Serotype 23F713 (506.7 to 1001.9)
SecondaryGeometric Mean Fold Rises (GMFRs) in Serotype-specific OPA Titers 1 Month After Vaccination

OPA GMFRs were calculated along with corresponding 2-sided 95% CIs for pneumococcal serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F. GMFRs were computed as the fold rise in titer value at 1 month after vaccination compared to baseline (pre-vaccination). The CIs for GMFRs were back transformations of a CI based on the Student t distribution for the mean difference of the log-transformed assay results before vaccination and 1 month after vaccination.

Time frame:
Pre-vaccination to 1 month after vaccination
Reported as:
Geometric mean · fold rise
Geometric Mean Fold Rises (GMFRs) in Serotype-specific OPA Titers 1 Month After Vaccination
fold rise13vPnC: All Participants
Serotype 115.6 (12.33 to 19.82)
Serotype 35.5 (4.59 to 6.54)
Serotype 461.7 (42.80 to 88.99)
Serotype 511.2 (8.69 to 14.34)
Serotype 6A34.7 (24.39 to 49.44)
Serotype 6B21.9 (15.71 to 30.51)
Serotype 7F12.1 (9.84 to 14.76)
Serotype 9V6.8 (5.36 to 8.62)
Serotype 1413.2 (9.63 to 18.04)
Serotype 18C26.7 (19.39 to 36.86)
Serotype 19A24.9 (19.05 to 32.66)
Serotype 19F26.6 (19.89 to 35.63)
Serotype 23F50.4 (35.70 to 71.16)
SecondarySerotype-specific Immunoglobulin G (IgG) Geometric Mean Concentrations (GMCs) at Pre-vaccination and 1 Month After Vaccination

Pneumococcal IgG antibody against each of the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) was measured centrally using direct binding Luminex assay. Results were expressed as IgG concentrations. IgG concentrations were logarithmically transformed for analysis; geometric means calculated and expressed as GMCs. Two (2)-sided 95% CIs were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed based on the Student t distribution.

Time frame:
Pre-vaccination and 1 month after vaccination
Reported as:
Geometric mean · microgram per milliliter (mcg/mL)
Serotype-specific Immunoglobulin G (IgG) Geometric Mean Concentrations (GMCs) at Pre-vaccination and 1 Month After Vaccination
microgram per milliliter (mcg/mL)13vPnC: All Participants
Pre-vaccination; Serotype 10.132 (0.109 to 0.161)
1 month after vaccination; Serotype 14.427 (3.423 to 5.726)
Pre-vaccination; Serotype 30.115 (0.094 to 0.141)
1 month after vaccination; Serotype 30.531 (0.437 to 0.646)
Pre-vaccination; Serotype 40.055 (0.045 to 0.068)
1 month after vaccination; Serotype 41.826 (1.387 to 2.404)
Pre-vaccination; Serotype 50.058 (0.046 to 0.075)
1 month after vaccination; Serotype 52.779 (1.972 to 3.915)
Pre-vaccination; Serotype 6A0.173 (0.133 to 0.224)
1 month after vaccination; Serotype 6A4.070 (2.915 to 5.684)
Pre-vaccination; Serotype 6B0.105 (0.080 to 0.138)
1 month after vaccination; Serotype 6B2.354 (1.631 to 3.396)
Pre-vaccination; Serotype 7F0.117 (0.092 to 0.150)
1 month after vaccination; Serotype 7F4.670 (3.629 to 6.010)
Pre-vaccination; Serotype 9V0.067 (0.054 to 0.082)
1 month after vaccination; Serotype 9V1.483 (1.131 to 1.944)
Pre-vaccination; Serotype 140.335 (0.252 to 0.447)
1 month after vaccination; Serotype 147.769 (5.844 to 10.328)
Pre-vaccination; Serotype 18C0.168 (0.131 to 0.216)
1 month after vaccination; Serotype 18C5.187 (4.026 to 6.682)
Pre-vaccination; Serotype 19A0.496 (0.391 to 0.629)
1 month after vaccination; Serotype 19A7.616 (5.786 to 10.026)
Pre-vaccination; Serotype 19F0.217 (0.171 to 0.275)
1 month after vaccination; Serotype 19F4.315 (3.241 to 5.744)
Pre-vaccination; Serotype 23F0.181 (0.143 to 0.228)
1 month after vaccination; Serotype 23F6.283 (4.524 to 8.727)
SecondaryGMFRs in Serotype-specific IgG From Before Vaccination to 1 Month After Vaccination

IgG GMFRs were calculated along with corresponding 2-sided 95% CIs for pneumococcal serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F. GMFRs were computed as the fold rise in concentrations at 1 month after vaccination compared to baseline (pre-vaccination). The CIs for GMFRs were back transformations of a CI based on the Student t distribution for the mean difference of the log-transformed assay results before vaccination and 1 month after vaccination.

Time frame:
Pre- vaccination to 1 month after vaccination
Reported as:
Geometric mean · fold rise
GMFRs in Serotype-specific IgG From Before Vaccination to 1 Month After Vaccination
fold rise13vPnC: All Participants
Serotype 133.445 (26.374 to 42.413)
Serotype 34.605 (3.839 to 5.524)
Serotype 432.960 (25.331 to 42.886)
Serotype 547.565 (36.867 to 61.368)
Serotype 6A23.587 (18.010 to 30.890)
Serotype 6B22.421 (17.045 to 29.493)
Serotype 7F39.843 (31.473 to 50.438)
Serotype 9V22.232 (17.426 to 28.362)
Serotype 1423.161 (17.179 to 31.227)
Serotype 18C30.833 (24.008 to 39.597)
Serotype 19A15.354 (12.116 to 19.459)
Serotype 19F19.892 (15.552 to 25.443)
Serotype 23F34.809 (26.436 to 45.833)

Adverse events

Collected over signing of informed consent form (Day 1) up to Day 43. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
13vPnC: 6 to <18 Years0/53 (0%)0/53 (0%)49/53 (92.5%)
13vPnC: 18 to <65 Years0/153 (0%)0/153 (0%)121/153 (79.1%)
13vPnC: All Participants0/206 (0%)0/206 (0%)170/206 (82.5%)
Most frequent other events
Showing 10 of 32
Most frequent other events
Event13vPnC: 6 to <18 Years13vPnC: 18 to <65 Years13vPnC: All Participants
Pain at the injection siteGeneral disorders41/5296/145137/197
FatigueGeneral disorders18/4847/14265/190
Injection site swellingGeneral disorders16/4717/13633/183
MyalgiaMusculoskeletal and connective tissue disorders15/4938/13953/188
HeadacheNervous system disorders12/4933/14145/190
RednessGeneral disorders10/4710/13520/182
DiarrhoeaGastrointestinal disorders4/4826/14130/189
PyrexiaGeneral disorders7/488/13415/182
ArthralgiaMusculoskeletal and connective tissue disorders3/4819/13822/186
PharyngitisInfections and infestations3/532/1535/206

Baseline characteristics

Safety analysis set included all participants who received 1 dose of study vaccine.

Age, Continuous
Age, Continuous(years)13vPnC: 6 to <18 Years13vPnC: 18 to <65 YearsTotal
Mean12.7 ± 2.6649.0 ± 10.1239.6 ± 18.18
Sex: Female, Male
Sex: Female, Male(Participants)13vPnC: 6 to <18 Years13vPnC: 18 to <65 YearsTotal
Female227799
Male3176107
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)13vPnC: 6 to <18 Years13vPnC: 18 to <65 YearsTotal
Asian53153206
Non-Hispanic/non-Latino/not of Spanish origin53153206
08

Study locations

8 sites
  • Daido Clinic
    Nagoya, Aichi 457-8511, Japan
  • Nippon Kokan Fukuyama Hospital
    Fukuyama, Hiroshima 721-0927, Japan
  • Fukuyama City Hospital
    Fukuyama, Hiroshima 721-8511, Japan
  • Kawasaki Municipal Hospital
    Kawasaki, Kanagawa 210-0013, Japan
  • Nagano Prefectural Shinshu Medical Center
    Suzaka, Nagano 382-8577, Japan
  • Medical Co.LTA PS Clinic
    Fukuoka, 812-0025, Japan
  • Fukuoka Children's Hospital
    Fukuoka, 813-0017, Japan
  • National Hospital Organization Kumamoto Medical Center
    Kumamoto, 860-0008, Japan
09

References and documents

Publications

  • Yamazaki Y, Ikeda M, Imada T, Furuno K, Mizukami T, de Solom R, Shoji Y, Oe M, Aizawa M, Giardina PC, Schmoele-Thoma B, Scott DA. A phase 3, multicenter, single-arm, open-label study to assess the safety, tolerability, and immunogenicity of a single dose of 13-valent pneumococcal conjugate vaccine in Japanese participants aged 6-64 years who are considered to be at increased risk of pneumococcal disease and who are naive to pneumococcal vaccines. Vaccine. 2021 Oct 15;39(43):6414-6421. doi: 10.1016/j.vaccine.2021.08.106. Epub 2021 Sep 23. PubMed 34563397 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2018 to primary completion in Nov 2018, 4 months.

Results were first posted in Dec 2019, 1 year after primary completion.

Of 81 industry-sponsored phase 3 interventional studies under Pneumococcal Infections, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 23. This study's 4 months is below that.

Counting every sponsor, half of 82 studies reached it within 13 months; a quarter within 9 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 20, 2018
First posted
Jun 27, 2018
StartActual
Jul 12, 2018
Primary completionActual
Nov 16, 2018
CompletionActual
Nov 16, 2018
Results first posted
Dec 10, 2019
Last update
Feb 18, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 18, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03571607
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Jun 27, 2018
Start date
Jul 12, 2018
Primary completion
Nov 16, 2018
Completion
Nov 16, 2018
Results posted
Dec 10, 2019
Last update
Feb 18, 2020

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: 13-valent pneumococcal vaccine

Start the discussion